Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A transgenic mouse model for mammary carcinogenesis

B Li1, K L Murphy, R Laucirica

  • 1Hughes Institute, Roseville, Minnesota 55113, USA.

Oncogene
|March 31, 1998
PubMed
Summary

A specific p53 mutation (arginine-to-histidine at amino acid 175) accelerates mammary gland tumor development in mice. This gain-of-function mutation increases genomic instability, offering a new model for breast cancer research.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bone marrow cells regenerate infarcted myocardium.

Nature·2001
Same author

An improved synthesis of the saponin, polyphyllin D.

Carbohydrate research·2001
Same author

A COL1A1 Sp1 binding site polymorphism predisposes to osteoporotic fracture by affecting bone density and quality.

The Journal of clinical investigation·2001
Same author

Noninvasive diagnosis of renal-allograft rejection by measurement of messenger RNA for perforin and granzyme B in urine.

The New England journal of medicine·2001
Same author

MHC-independent allograft vascular disease: mRNA profile in the MHC congenic rat heterotopic cardiac transplant model.

Transplantation proceedings·2001
Same author

Endothelin is a potent inhibitor of matrix metalloproteinase-2 secretion and activation in rat mesangial cells.

American journal of physiology. Renal physiology·2001

Area of Science:

  • Oncology
  • Genetics
  • Molecular Biology

Background:

  • Missense mutations in the p53 tumor suppressor gene are common in breast cancer.
  • Amino acid 175 is a frequent mutation site, often resulting in arginine-to-histidine substitutions with gain-of-function properties.

Purpose of the Study:

  • To characterize a transgenic mouse model expressing a mutated p53 (172 R-H) construct in the mammary gland.
  • To investigate the specific effects of this p53 mutation on mammary tumorigenesis and tumor characteristics.

Main Methods:

  • Generation of transgenic mice with mammary gland-specific expression of p53 172(R-H) using a whey acidic protein (WAP) promoter.
  • Treatment with the chemical carcinogen dimethylbenz(a)anthracene to induce mammary tumors.
  • Analysis of tumor latency, burden, apoptosis, cell proliferation, genomic instability, and ploidy.

Related Experiment Videos

Main Results:

  • Transgene expression alone did not affect normal mammary development.
  • Transgenic mice exhibited significantly shorter tumor latency and greater tumor burden after carcinogen treatment compared to controls.
  • Tumors in transgenic mice showed increased genomic instability and aneuploidy, but not altered apoptosis or proliferation rates.

Conclusions:

  • The p53 172(R-H) mutation accelerates mammary tumorigenesis and confers genomic instability.
  • This transgenic mouse model is valuable for studying early events in mammary tumor development.
  • The model can be utilized for preclinical testing of novel chemotherapeutic strategies.